SCHEMBL26985133

SCHEMBL26985133

Cc1c(Cc2ccnc(N(S(C)(=O)=O)S(C)(=O)=O)c2F)cncc1Nc1ccc(Br)cc1F

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.32
▸ CLK1 P49759 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ GRK2 P25098 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CTDSP1 Q9GZU7 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ TP53 P04637 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MAP2K1 Q02750 2/20 0.30
▸ ABCB11 O95342 1/20 0.30
▸ NQO2 P16083 1/20 0.30
▸ MAP2K2 P36507 1/20 0.30
▸ EGFR P00533 1/20 0.30
▸ RET P07949 1/20 0.30
▸ KIF5B P33176 1/20 0.30
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746495 1.00 KMT2A (0.32) KMT2ACLK1MAPK1GAAL3MBTL1
SCHEMBL26984886 0.87 KMT2A (0.34) KMT2ACLK1MAPK1GAAL3MBTL1
SCHEMBL30746469 0.87 KMT2A (0.34) KMT2ACLK1MAPK1GAAL3MBTL1
SCHEMBL26985172 0.84 SLC22A12 (0.36) KMT2ACLK1MAPK1GAAMAP2K1
SCHEMBL30746491 0.84 SLC22A12 (0.36) KMT2ACLK1MAPK1GAAMAP2K1
SCHEMBL30746420 0.82 RAF1 (0.42) KMT2ACLK1MAPK1GAAL3MBTL1
SCHEMBL26985095 0.82 RAF1 (0.42) KMT2ACLK1MAPK1GAAL3MBTL1
SCHEMBL30746672 0.82 MAPK1 (0.35) CLK1MAPK1GAAL3MBTL1TP53
SCHEMBL26984845 0.82 MAPK1 (0.35) CLK1MAPK1GAAL3MBTL1TP53
SCHEMBL30746429 0.81 FPR2 (0.37) GAAMAP2K1ABCB11NQO2MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 KMT2A 1855/4885CLK1 295/4885MAPK1 3/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 KMT2A 1441/4885CLK1 458/4885MAPK1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback